Investing.com - Compass Therapeutics, reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Compass Therapeutics, announced earnings per share of $-0.12 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.10 on revenue of $0.00.
Compass Therapeutics, shares are down 28.9% from the beginning of the year and are trading at $4.19 , down-from-52-week-high.
Compass Therapeutics, shares lost 1.41% in intra-day trade the report.
Compass Therapeutics, follows other major Healthcare sector earnings this month
Compass Therapeutics,'s report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar